PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Jun 07, 2019
-- Emflaza is the only approved treatment for all patients two and over living with Duchenne muscular dystrophy -- SOUTH PLAINFIELD, N.J. , June 7, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration ( FDA ) approved the company's
Additional Formats
Jun 03, 2019
SOUTH PLAINFIELD, N.J. , June 3, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Emily Hill to Chief Financial Officer. Ms. Hill joined PTC Therapeutics in November 2013 and was most recently Senior Vice President and Head of Investor Relations.
Additional Formats
May 31, 2019
SOUTH PLAINFIELD, N.J. , May 31, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 20, 2019 it approved non-statutory stock options to purchase an aggregate of 76,250 shares of its common stock to 15 new employees.  The awards were made pursuant to the NASDAQ
Additional Formats
May 30, 2019
SOUTH PLAINFIELD, N.J. , May 30, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Jefferies Healthcare Conference on Thursday, June 6th at 4:00 p.m. ET . The presentation will be webcast live on the Events and
Additional Formats
May 20, 2019
- $545,000 awarded to help improve Duchenne muscular dystrophy diagnosis and screening across the globe - SOUTH PLAINFIELD, N.J. , May 20, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three funding recipients from PRIORITY, an annual program to support outstanding
Additional Formats
May 09, 2019
- $4 million equity investment to advance delivery device R&D for CNS gene therapy portfolio and other company operations - SOUTH PLAINFIELD, N.J. and IRVINE, Calif. , May 9, 2019 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) and MRI Interventions, Inc.
Additional Formats
May 08, 2019
SOUTH PLAINFIELD, N.J. , May 8, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Bank of America Merrill Lynch Healthcare Conference Tuesday, May 14 th at 1:40 p.m.
Additional Formats
May 07, 2019
Babies with Type 1 SMA from Part 1 of FIREFISH continue to achieve motor milestones including standing 58% of patients experienced an improvement of at least 3 points on MFM32 scale vs. baseline after 12 months of treatment in Part 1 of SUNFISH No drug related safety findings leading to withdrawal
Additional Formats
May 03, 2019
SOUTH PLAINFIELD, N.J. , May 3, 2019 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on April 23, 2019 it approved non-statutory stock options to purchase an aggregate of 210,900 shares of its common stock to 27 new employees.
Additional Formats
May 02, 2019
Translarna™ Approved by Brazilian Health Regulatory Authority (ANVISA) Waylivra™ Receives Positive CHMP Opinion SOUTH PLAINFIELD, N.J. , May 2, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending
Additional Formats